We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Votes BioMarin’s DrisapersenTrials Not Persuasive
FDA Advisory Panel Votes BioMarin’s DrisapersenTrials Not Persuasive
With a mixed bag of results and much at stake for BioMarin’s Duchenne muscular dystrophy treatment drisapersen, FDA reviewers overwhelmingly decided the largest, most complete trial in the drug’s development weakened “promising” findings from earlier studies.